Acetylon Pharmaceuticals Celebrates Headquarters Expansion In Boston’s Innovation District
3/20/2014 10:09:04 AM
BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced the expansion of its headquarters facility located in Boston’s Innovation District. Martin J. Walsh, Mayor of Boston, and Robert K. Coughlin, President and Chief Executive Officer of MassBio, are scheduled to join Acetylon employees and other invited guests this morning in a ribbon cutting ceremony at the Company.
Help employers find you! Check out all the jobs and post your resume.
comments powered by